ECSP066595A - Anticuerpo del receptor anti-igf-i - Google Patents

Anticuerpo del receptor anti-igf-i

Info

Publication number
ECSP066595A
ECSP066595A EC2006006595A ECSP066595A ECSP066595A EC SP066595 A ECSP066595 A EC SP066595A EC 2006006595 A EC2006006595 A EC 2006006595A EC SP066595 A ECSP066595 A EC SP066595A EC SP066595 A ECSP066595 A EC SP066595A
Authority
EC
Ecuador
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
EC2006006595A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Tavares
Rajeeva Singh
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ECSP066595A publication Critical patent/ECSP066595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2006006595A 2003-12-08 2006-05-31 Anticuerpo del receptor anti-igf-i ECSP066595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
ECSP066595A true ECSP066595A (es) 2006-10-17

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006595A ECSP066595A (es) 2003-12-08 2006-05-31 Anticuerpo del receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (fr)
JP (1) JP2008502589A (fr)
KR (1) KR20070001883A (fr)
CN (1) CN1886424A (fr)
AU (1) AU2004303792A1 (fr)
BR (1) BRPI0417406A (fr)
CA (1) CA2548065A1 (fr)
CR (1) CR8426A (fr)
EA (1) EA009807B1 (fr)
EC (1) ECSP066595A (fr)
IL (1) IL174770A0 (fr)
MX (1) MXPA06005540A (fr)
NO (1) NO20063155L (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
KR20130065665A (ko) * 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
WO2013055699A1 (fr) * 2011-10-10 2013-04-18 Children's Hospital Los Angeles Nouvelle asparaginase et nouvelles méthodes de traitement des maladies associées à la dépendance de l'asparagine
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CN110691794B (zh) * 2017-05-30 2023-10-27 帝人制药株式会社 抗igf-i受体抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135688A2 (fr) * 1998-12-04 2001-09-26 Novartis AG Methodes et compositions utiles pour cibler le recepteur alpha(nu)-beta(3)active par la vitronectine
UY27087A1 (es) * 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Also Published As

Publication number Publication date
NO20063155L (no) 2006-08-11
EP1692176A1 (fr) 2006-08-23
JP2008502589A (ja) 2008-01-31
IL174770A0 (en) 2006-08-20
CN1886424A (zh) 2006-12-27
MXPA06005540A (es) 2006-08-17
AU2004303792A1 (en) 2005-07-07
KR20070001883A (ko) 2007-01-04
EA009807B1 (ru) 2008-04-28
CR8426A (es) 2007-12-04
CA2548065A1 (fr) 2005-07-07
EP1692176A4 (fr) 2008-11-12
BRPI0417406A (pt) 2007-04-03
EA200600931A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
ES2571235T3 (es) Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
MX2019012811A (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion.
UA94388C2 (ru) Антиинтегриновый иммуноконьюгат и способы лечения с его помощью
NO20070945L (no) Induksjon av apoptose i tumorceller som uttrykker toll-lignende reseptor
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
ECSP066595A (es) Anticuerpo del receptor anti-igf-i
CU20130130A7 (es) Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
WO2006138729A3 (fr) Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007100640A3 (fr) Traitement du cancer a l'aide d'antagonistes du recepteur de l'hormone de croissance
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
EA200601405A1 (ru) Гуманизированное антитело
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
CO6331345A2 (es) Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma
PE20130460A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
AR078667A1 (es) Moduladores de activador del factor de crecimiento de hepatocitos (hgfa)
DOP2009000003A (es) Anticuerpo antagonista para el tratamiento del cancer
Sandomenico 3D1, a novel anti-nodal monoclonal antibody to target melanoma
PE20091437A1 (es) Anticuerpos modificadores de enfermedades cancerosas